Sangamo Therapeutics, Inc. (SGMO)
| Market Cap | 607.28M |
| Revenue (ttm) | 112.65M |
| Net Income (ttm) | -176.33M |
| Shares Out | 146.69M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,960,889 |
| Open | 4.07 |
| Previous Close | 4.00 |
| Day's Range | 3.98 - 4.18 |
| 52-Week Range | 3.48 - 12.83 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 16.37 (+295.4%) |
| Earnings Date | May 5, 2022 |
About SGMO
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-...
Financial Performance
In 2021, SGMO's revenue was $110.70 million, a decrease of -6.34% compared to the previous year's $118.19 million. Losses were -$178.29 million, 47.3% more than in 2020.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is 16.37, which is an increase of 295.41% from the latest price.
News
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 6.25% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2022 FINANCIAL RESULTS
Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Soc...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Data at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Sangamo Therapeutics, Inc. for Potential Breaches of Fidu...
NEW YORK , April 4, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim i...
Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength?
Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the ...
Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell T...
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF CAR-TREG CELL THERAPY TX200 IN KIDNEY TRANSPLANTATION
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highligh...
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2...
The Sell Off In Gene Editing Stocks Continues. Time To Buy?
Our theme of Gene Editing stocks continues to underperform, declining by about 16% year-to-date in 2022, compared to the S&P 500 which is down by about 6% over the same period. The theme also declined b...
Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial
Sangamo Therapeutics Inc SGMO announced updated preliminary results from the Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), Fabry disease gene therapy candidate. Get the Inside Access Trad...
Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary results from the Phase 1/2 STAAR clinical study evaluating i...
Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights and obligations related to SAR4451...
Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will provide a corporate presentation at the H.C. Wainwright BIO...
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Throu...
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/...
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 ...
Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet
The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i...
Why Did Sangamo Stock Jump 20% Today?
Sangamo Therapeutics Inc (NASDAQ: SGMO) announced preliminary results from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a gene therapy candidate for Fabry disease. As of t...
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights. “W...
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme ...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgag...
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial r...
Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.